Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for celg
-2.39 (-2.04%)
Real-time:   9:54AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 110.39 - 115.46
52 week 66.85 - 119.84
Open 112.65
Vol / Avg. 860,478.00/4.62M
Mkt cap 91.68B
P/E 60.09
Div/yield     -
EPS 1.91
Shares 798.70M
Beta 1.09
Inst. own 83%
Jan 29, 2015
Q4 2014 Celgene Corp Earnings Release - 9:30AM EST - Add to calendar
Dec 7, 2014
Celgene Presentation at the American Society of Hematology - Webcast
Nov 11, 2014
Celgene Corp at Credit Suisse Healthcare Conference
Oct 23, 2014
Q3 2014 Celgene Corp Earnings Release
Oct 23, 2014
Q3 2014 Celgene Corp Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 25.65% 22.33%
Operating margin 32.52% 27.86%
EBITD margin - 36.25%
Return on average assets 12.75% 11.55%
Return on average equity 38.41% 25.70%
Employees 5,100 -
CDP Score - 80 C


86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

Officers and directors

Robert J. Hugin Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Tuomo Patsi President - Europe, Middle East and Africa (EMEA)
Bio & Compensation  - Reuters
Scott Smith President - Inflammation & Immunology
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 60
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 68
Bio & Compensation  - Reuters